U.S. markets closed

Verrica Pharmaceuticals Inc. (VRCA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.6500-0.1900 (-6.69%)
At close: 04:00PM EDT
2.7300 +0.08 (+3.02%)
After hours: 04:16PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close2.8400
Bid2.5800 x 900
Ask3.0700 x 800
Day's Range2.6500 - 2.8100
52 Week Range1.7700 - 13.6400
Avg. Volume163,723
Market Cap108.899M
Beta (5Y Monthly)2.04
PE Ratio (TTM)N/A
EPS (TTM)-1.5480
Earnings DateNov 10, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for VRCA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Verrica Pharmaceuticals Inc.
    Daily – Vickers Top Buyers & Sellers for 07/06/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    3 months agoArgus Research
View more
  • GlobeNewswire

    Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference

    WEST CHESTER, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 3:30 p.m. ET. Participants may access a live webcast of the event through the following link: https://journey

  • Simply Wall St.

    Is Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Popular Amongst Insiders?

    A look at the shareholders of Verrica Pharmaceuticals Inc. ( NASDAQ:VRCA ) can tell us which group is most powerful...

  • GlobeNewswire

    Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results

    Verrica held Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of the NDA for VP-102 for the treatment of molluscum contagiosum Verrica has begun working with Piramal Pharma Solutions for production of bulk solution and reaffirms plans to resubmit NDA for VP-102 for molluscum contagiosum in Q1 2023 Raised approximately $28.5 million of gross proceeds in an underwritten public offering WEST CHESTER, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Verrica Ph